Yuqiao Pan

Yuqiao Pan

Auto-generated profile, based on publicly available information

Yuqiao Pan

Nuclear Dynamics and Cancer Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania. 1

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2024 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
Takahiko MurayamaTakahiko Murayama
Takahiko Murayama
NMNavin R Mahadevan
Navin R Mahadevan
CMCatherine B. Meador
Catherine B. Meador
EIElena V. Ivanova
Elena V. Ivanova
YPYuqiao Pan
Yuqiao Pan
ICIsrael Cañadas
Israel Cañadas
Small-cell lung cancer (SCLC) is the most lethal type of lung cancer. Paradoxically, this tumor displays an initial exquisite response to chemotherapy; however, at relapse, the tumor is highly resistant to subsequent available therapies. Here, we report that the expression of three prime repair exonuclease 1 (TREX1) is strongly induced in chemoresistant SCLCs. Assay for transposase-accessible chromatin using sequencing and chromatin immunoprecipitation sequencing revealed a significant increase in chromatin accessibility and transcriptional activity of TREX1 gene locus in chemoresistant SCLCs. Analyses of human SCLC tumors and patient-derived xenografts (PDX) also showed an increase in TREX1 expression in postchemotherapy samples. TREX1 depletion caused the activation of cyclic GMP-AMP synthase stimulator of interferon gene pathway due to cytoplasmic accumulation of damage-associated double-stranded DNA, inducing immunogenicity and enhancing the sensitivity of drug-resistant cells to chemotherapy. These findings suggest TREX1 upregulation may partially contribute to the survival of resistant cells, and its inhibition may represent a promising therapeutic strategy to enhance antitumor immunity and potentiate the efficacy of chemotherapy and/or immunotherapy in chemoresistant SCLCs. Significance: In this study, we show that targeting TREX1 induces an innate immune response and resensitizes SCLC cells to chemotherapy, representing a promising novel target for “immunologically” cold tumors, such as SCLC.

12 September 2024
Verified
Other
Open access
Takahiko MurayamaTakahiko Murayama
Takahiko Murayama
NMNavin R Mahadevan
Navin R Mahadevan
CMCatherine B. Meador
Catherine B. Meador
EIElena V. Ivanova
Elena V. Ivanova
YPYuqiao Pan
Yuqiao Pan
ICIsrael Cañadas
Israel Cañadas
Small-cell lung cancer (SCLC) is the most lethal type of lung cancer. Paradoxically, this tumor displays an initial exquisite response to chemotherapy; however, at relapse, the tumor is highly resistant to subsequent available therapies. Here, we report that the expression of three prime repair exonuclease 1 (TREX1) is strongly induced in chemoresistant SCLCs. Assay for transposase-accessible chromatin using sequencing and chromatin immunoprecipitation sequencing revealed a significant increase in chromatin accessibility and transcriptional activity of TREX1 gene locus in chemoresistant SCLCs. Analyses of human SCLC tumors and patient-derived xenografts (PDX) also showed an increase in TREX1 expression in postchemotherapy samples. TREX1 depletion caused the activation of cyclic GMP-AMP synthase stimulator of interferon gene pathway due to cytoplasmic accumulation of damage-associated double-stranded DNA, inducing immunogenicity and enhancing the sensitivity of drug-resistant cells to chemotherapy. These findings suggest TREX1 upregulation may partially contribute to the survival of resistant cells, and its inhibition may represent a promising therapeutic strategy to enhance antitumor immunity and potentiate the efficacy of chemotherapy and/or immunotherapy in chemoresistant SCLCs.Significance: In this study, we show that targeting TREX1 induces an innate immune response and resensitizes SCLC cells to chemotherapy, representing a promising novel target for “immunologically” cold tumors, such as SCLC.

12 September 2024
Verified
Other
Open access
Takahiko MurayamaTakahiko Murayama
Takahiko Murayama
NMNavin R Mahadevan
Navin R Mahadevan
CMCatherine B. Meador
Catherine B. Meador
EIElena V. Ivanova
Elena V. Ivanova
YPYuqiao Pan
Yuqiao Pan
ICIsrael Cañadas
Israel Cañadas
Drug transporter expression levels in H69AR vs H69

16 March 2026
Verified
Other
Open access
Takahiko MurayamaTakahiko Murayama
Takahiko Murayama
NMNavin R Mahadevan
Navin R Mahadevan
CMCatherine B. Meador
Catherine B. Meador
EIElena V. Ivanova
Elena V. Ivanova
YPYuqiao Pan
Yuqiao Pan
ICIsrael Cañadas
Israel Cañadas
Small-cell lung cancer (SCLC) is the most lethal type of lung cancer. Paradoxically, this tumor displays an initial exquisite response to chemotherapy; however, at relapse, the tumor is highly resistant to subsequent available therapies. Here, we report that the expression of three prime repair exonuclease 1 (TREX1) is strongly induced in chemoresistant SCLCs. Assay for transposase-accessible chromatin using sequencing and chromatin immunoprecipitation sequencing revealed a significant increase in chromatin accessibility and transcriptional activity of TREX1 gene locus in chemoresistant SCLCs. Analyses of human SCLC tumors and patient-derived xenografts (PDX) also showed an increase in TREX1 expression in postchemotherapy samples. TREX1 depletion caused the activation of cyclic GMP-AMP synthase stimulator of interferon gene pathway due to cytoplasmic accumulation of damage-associated double-stranded DNA, inducing immunogenicity and enhancing the sensitivity of drug-resistant cells to chemotherapy. These findings suggest TREX1 upregulation may partially contribute to the survival of resistant cells, and its inhibition may represent a promising therapeutic strategy to enhance antitumor immunity and potentiate the efficacy of chemotherapy and/or immunotherapy in chemoresistant SCLCs.Significance:In this study, we show that targeting TREX1 induces an innate immune response and resensitizes SCLC cells to chemotherapy, representing a promising novel target for “immunologically” cold tumors, such as SCLC.

12 September 2024
Verified
Other
Open access
Takahiko MurayamaTakahiko Murayama
Takahiko Murayama
NMNavin R Mahadevan
Navin R Mahadevan
CMCatherine B. Meador
Catherine B. Meador
EIElena V. Ivanova
Elena V. Ivanova
YPYuqiao Pan
Yuqiao Pan
ICIsrael Cañadas
Israel Cañadas
TREX1 depletion suppresses SCLC growth and induces IFN response. A, Expression levels of TREX1, IRF3, and p-IRF3 in H69AR and H196 were compared by immunoblotting between cells transduced with Scr and sgTREX1 (#1 and #2). B, Growth curves of H69AR and H196 cells were compared between siCtrl and siTREX1 (#1 and #2; mean ± SEM; n = 3). C, GSEA analysis with H (hallmark) gene sets, based on RNA-seq results of siTREX1 vs. siCtrl H69AR cells. D, Expression levels of IFNB and IFIT1 genes in cells transfected with siCtrl and siTREX1 (#1) were compared by qPCR (mean ± SEM; n = 3). E and F, HLA-A, HLA-B, and HLA-C (E) and PDL1 (F) expressions in H69AR and H196 cells transfected with siCtrl or siTREX1 were compared by flow cytometry analysis. Data are representative of three independent experiments (Left). Mean fluorescence intensity was quantified by FlowJo (Right; n = 3). Cells were analyzed 3 days after siRNA transfection. G, (Left) Schematic of cancer cell–T-cell coculture, performed at a stimulator/responder (S/R) ratio of 1:1. (Right) IL2 secretion from 72 hours cocultures of RPP-A-EtopR (Scr or sgTrex1) or parental RPP-A cells ± 24-hour IFNγ (100 ng/mL) stimulation and no (nil), parental untransduced BW5147.3 (P), or Trav14D-3-DV8; Trbv29 transgenic BW5147.3 (TCR) T cells. BW (−/+) and TCR (−/+) bars represent P or TCR T cells alone without (−) or with (+) PMA (50 nmol/L) and ionomycin (1 μg/mL). ^, above assay threshold of detection (mean ± SEM; n = 4). Data represent mean ± SEM. ns, not significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001 by unpaired Student t test (D, E and F), one-way ANOVA followed by Dunnett’s multiple comparisons test (B) and two-way ANOVA followed by Tukey’s multiple comparisons test (G).

12 September 2024
Verified
Other
Open access
Takahiko MurayamaTakahiko Murayama
Takahiko Murayama
NMNavin R Mahadevan
Navin R Mahadevan
CMCatherine B. Meador
Catherine B. Meador
EIElena V. Ivanova
Elena V. Ivanova
YPYuqiao Pan
Yuqiao Pan
ICIsrael Cañadas
Israel Cañadas
Information of patients with SCLC